Biblio
Inhibition of serine/arginine-rich protein kinase-1 (SRPK1) prevents cholangiocarcinoma cells induced angiogenesis. Toxicol In Vitro. 2022:105385.
Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma. Front Oncol. 2023;13:1184900.
Targeting MYC at the intersection between cancer metabolism and oncoimmunology. Front Immunol. 2024;15:1324045.
.